Introduction
of the DNA into the genome and due to the natural turnThe primary physiological defect in cystic fibrosis (CF) is over of epithelial cells, repeat applications will be necesthe failure of electrogenic chloride ion secretion across sary to provide a long-term treatment for CF. The the epithelia of many organs, including the lungs, intesrepeated use of adenoviral vectors is limited by the antitine and pancreas. 1 Current treatments are aimed at genic nature of the adenoviral proteins. [3] [4] [5] [6] [7] [8] Experiments in alleviating some of the symptoms of CF rather than proboth cotton rats and Rhesus monkeys show that the viding a cure and none are able to abolish the cycle of delivery of adenovirus is associated with an inflammarecurrent airway infections which gradually destroy lung tory response due to expression of adenovirus early and function resulting in premature death.
late proteins in transfected cells. Several groups have CF is caused by a variety of mutations in the cystic tried to attenuate this inflammatory response by creating fibrosis transmembrane conductance regulator (CFTR) a new generation of adenoviral vectors. These are assogene which encodes a cAMP-dependent chloride channel ciated with more stable expression of the transfected gene located in the apical membrane of epithelial cells.
2 Epibut do not completely abolish the inflammatory thelial cells from CF patients fail to secrete chloride ions response. 3, 8 (Cl − ) in response to agents which increase intracellular Cationic liposomes represent an alternative to adenovicAMP. Since the problems arising in CF result from ral vectors for the in vivo delivery of CFTR cDNA. Lipomutations in a single gene, the possibility exists that the somes are nonimmunogenic, have no specific cell tropism introduction of a normal copy of the gene into the epiand can be used to deliver DNA to many cells types thelia could provide a treatment for the disease, or affect including nondividing airway epithelial cells. 9, 10 The a cure if the gene transfer was permanent.
ability of cationic liposomes to deliver the CFTR gene has Viral and nonviral approaches have been used to been evaluated in CF mice. [11] [12] [13] These studies showed that deliver a functional CFTR gene to airway epithelia.
after a single delivery of a plasmid containing the CFTR cDNA complexed with cationic liposomes a cAMPdependent chloride secretion could be detected in tracheal epithelium. Gene transfer has also been detected in transient detection of cAMP-sensitive potential changes indicative of chloride secretion. 14, 15 This study used a CF null mouse model (Cftr tm1Cam ) to assay the safety and efficacy of repeat delivery of a CFTR expression vector complexed with cationic liposomes to the trachea of these mice.
Results
The mice used were aged between 22 and 100 days with a mean age of 47.8 ± 2.0 days. All the groups studied had a mean age close to this value with the exception of the group of untreated CF null −/− mice which were 36.5 ± 3.8 days old. The average weight of the CF null mice was lower than that of age-matched wild-type mice as CF mice thrive less well and are runted compared to their normal littermates. 16 However, the age of the animals is not as important as it was in earlier studies, 16, 17 as this study used the protocol developed by MacVinish et al 13 designed to separate the calcium-dependent and cAMP-dependent chloride secretory currents. In certain tissues, forskolin has been shown to raise the level of intracellular calcium and cAMP, so part of the forskolin response may reflect calcium-mediated chloride secretion through non-CFTR channels. 18 MacVinish et al 13 mice. Amiloride was added in a concentration which completely blocks electrogenic sodium absorption, which if present will reduce the electrochemical gradient for not differ significantly from the group given two mock chloride exit through the apical face of the tracheal epitransfections ( Figure 1 ). thelium cells. As the extent of sodium absorption varies in different tissues, blocking sodium transport will hypcAMP-dependent chloride secretion erpolarise the apical membrane to a level where all epiFollowing the addition of amiloride and TBHQ/A23187, thelia experience the same condition for measuring the the forskolin-sensitive SCC response (FSSCC) can clearly chloride secretory response. No significant difference in distinguish between wild-type (12.9 ± 1.4 A cm
, n = the mean basal short circuit currents was seen between 23) and CF null (−/−) tracheas (4.0 ± 0.9 A cm −2
, n = 15), any of the groups. Only one group, receiving two doses P Ͻ 0.0001 ( Figure 3 ). Two separate groups of CF null of pTRIAL10CFTR2:DC-Chol/DOPE, showed a signifimice were transfected with a single dose of pTRIALcant difference in the mean response to amiloride com-10CFTR2:DC-Chol/DOPE. Mice killed 2 days after transpared with the untreated wild-type and CF null tracheas fection had a forskolin response of 13.7 ± 2.1 A cm −2 (n (P Ͻ 0.05).
= 10). This was significantly greater than the FSSCC of untreated CF null mice (P Ͻ 0.0001) and not significantly different from the FSSCC of untreated wild-type mice Calcium-dependent chloride secretion The calcium-ATPase inhibitor TBHQ and the calcium (Figure 3 ). Mice killed 10 days after transfection had a forskolin response which had returned to 6.0 ± 1.5 A ionophore A23187 cause a steep increase in SCC which usually peaks at approximately 10 min and then declines cm −2 (n = 7), significantly less than that of the wild-type tracheas (P Ͻ 0.05) but not significantly different from to a plateau after 20 min (Figure 2 ). Only the group given two deliveries of pTRIAL10CFTR2:DC-Chol/DOPE that of the CF null tracheas (Figure 3) . A third group of mice was transfected with two doses showed a significant difference in the mean maximal response to TBHQ/A23187 compared with untreated of pTRIAL10CFTR2:DC-Chol/DOPE, on day 0 and again on day 10, and killed on day 12. The forskolin response wild-type and CF null tracheas (P Ͻ 0.01) (Figure 1) . However, the TBHQ/A23187 response of this group did of these mice was 16.3 ± 3.4 A cm −2 (n = 6). This was not significantly different from the forskolin response of the group assayed 2 days after a single transfection or that of untreated wild-type mice (Figure 3) . A fourth group of CF null mice were transfected twice with a control plasmid, pTRIAL10, which did not contain the CFTR cDNA. The mean response to forskolin when assayed on day 12 was 6.8 ± 1.8 A cm −2 (n = 6), significantly less than that of mice treated with the expression plasmid (P Ͻ 0.05) and not significantly different from the forskolin response of untreated CF null mice or mice assayed 10 days after a single transfection (Figure 3) .
In all instances the FSSCC was sensitive to the addition of frusemide which blocks entry of Cl − into the cell across the basolateral membrane via the co-transporter ( Figure  2 ).
Histology
Examination of lung sections stained with haematoxylin and eosin did not reveal any inflammatory responses, even after two deliveries of pTRIAL10CFTR2:DCChol/DOPE. Lungs taken from treated and untreated mice were indistinguishable and showed no histological differences. Figure 4 shows representative sections of lungs taken from treated (a) and untreated mice (b). Sec- bronchial lumina. The alveolae throughout the lungs have shown that, although the first delivery can correct the CF defect, subsequent deliveries are less able to generate a response especially at high doses of vector. 24 It appears that this is due to induction of acute T cellmediated inflammatory reactions against adenoviral proteins, 3,4,8 which destroys cells which have been successfully infected by adenovirus leading to reduced expression of CFTR. Second generation adenoviral vectors which express fewer viral proteins give reduced inflammatory responses but still contribute to the formation of neutralising antibodies which block subsequent gene transfer. [27] [28] [29] These humoral responses are compounded by the finding that over 96% of CF patients carry at least one antibody subtype against adenovirus. 30 Gene expression can be prolonged by the addition of interleukin-12 (IL-12) or interferon gamma (IFN-␥) at the time of transfection as they diminish the activity of the subgroup of T helper cells involved in the inflammatory response and the production of neutralising antibody. 31 Co-administration of immunosuppressive drugs (cyclosporin) can also be used to reduce the immune response.
To date, clinical trials using a liposome vector to deliver a single dose of CFTR to the nasal epithelium have produced no evidence of adverse clinical effects or immunohistological changes in CF patients. 14, 15, 26 Due to the problems associated with using adenoviral vectors in a multidosing regimen, this study was undertaken to establish whether a second application of a DNA plasmid complexed with liposome would result in a similar level of cAMP-stimulated Cl − current, after the response to the first application had subsided.
CF null tracheas should not respond to forskolin well as cAMP in some tissues, and this residual forskolin response could be due to Cl − secretion through calciumactivated channels, 18 or by another route. The previous showed a normal inconspicuous flat pneumocyte lining addition of TBHQ and A23187 was used to maximise with no inflammatory cells or oedema fluid in the intracellular calcium concentrations eliminating further alveolar spaces. Lungs were chosen to assess the increases by forskolin which could lead to non-CFTRinflammatory responses since the transfection mixture dependent Cl − secretion. Whatever the reason for the will be in longer contact with this tissue than the trachea residual forskolin sensitive currents in CF mice the data and it was speculated that greatest damage would be show that tracheas from wild-type mice have a signifiexpected at this site.
cantly higher FSSCC response than those from CF mice. It has been demonstrated that sodium absorption (measured as the response to amiloride) is reduced in the Discussion trachea of CF null mice. 11, 13, 17, 32 Here the response was smaller in the CF group but was not significantly differPhase I clinical trials using either adenoviral or liposome vectors to deliver the CFTR gene to the airways of CF ent to the amiloride response of untreated wild-type tracheas. Reference to Figure 1 shows that the response to patients have been completed in both the USA and Europe. 14, 15, [21] [22] [23] [24] [25] [26] These trials have provided data suggesting amiloride and to TBHQ/A23187 in the group receiving two doses of CFTR plasmid (group e) were significantly that gene transfer can be used to introduce a functional copy of CFTR into human airway epithelial cells. Howlarger than those in untreated controls (group a). However, neither result was significantly different when comever, CFTR function has only been measurable for up to 4 weeks following gene delivery in these trials. Many facpared with the more correct control, that is the group given two doses of the control plasmid, pTRIAL10 (group tors contribute to the length of gene expression; for example, turnover of epithelial cells, promoter inactif). It is also seen that the TBHQ/A23187 response in group e falls to normal levels at 30 min. Therefore we do vation or vector degradation. Since these plasmids are not capable of autonomous replication, it will be necesnot consider the increased response to amiloride in group e is of significance and is a result of the greater variance sary to give CF patients multiple deliveries of CFTR cDNA in order to treat their condition, at least until vecin this group. However the finding indicates the importance of removing all sodium transport before the ability tors are developed which can be maintained within a transfected cell.
to activate CFTR-dependent chloride secretion is measured. Repeat dose clinical trials using adenovirus vectors Earlier studies have shown that 2 days after the deliv-CFTR cDNA under the control of the Rous sarcoma virus 3′ long terminal repeat (RSV 3′LTR) promoter and ery of a single dose of CFTR cDNA complexed with liposomes to the upper airway a cAMP-stimulated Cl − ion pTRIAL10 which lacks the CFTR cDNA as a negative control. 13 current can be detected in the tracheal epithelium of CF null mice. 11, 13 The data here confirm these findings and Several groups of mice were studied in this experiment. extends them to show that 10 days after delivery of a single dose the forskolin response (a measure of CFTRdependent Cl − secretion) had returned to the level seen Controls: (a) Untreated wild-type mice (n = 23). Weight, in CF null tracheas. When such mice were transfected 22.9 ± 0.9 g; age, 53.0 ± 4.0 days (note: this cohort comwith a second dose of CFTR on day 10 and killed 2 days bined data from homozygote +/+ (n = 9) and heterolater it was found that the forskolin response was zygote +/− (n = 14) mice as the SCC responses of either restored such that it was not significantly different from group are indistinguishable). 16 (b) Untreated CF null that of wild-type mice or CF null mice given a single mice (−/−) (n = 15); weight, 13.4 ± 1.7; age, 36.5 ± 3.8. delivery. In the future it will be important to show, by adjusting the frequency of the administration, that the Transfected mice: (c) CF null mice transfected with pTRIgene transfer can permanently sustain the forskolin AL10CFTR2 on day 0 and killed on day 2 (n = 10); weight, response within the wild-type range.
17.7 ± 1.1 g; age, 48.1 ± 4.8 days. (d) CF null mice transExamination of lung sections after a single or double fected with pTRIAL10CFTR2 on day 0 and killed on day delivery of pTRIAL10CFTR2:DC-Chol/DOPE revealed 10 (n = 7); weight, 15.9 ± 2.8 g; age, 46.4 ± 3.9 days. (e) CF no indication of neutrophil infiltration or signs of cellular null mice transfected with pTRIAL10CFTR2 on day 0 and damage. The alveolar pneumocyte lining is very thin and day 10 and killed on day 12 (n = 6); weight, 19.4 ± 1.5 g; even minor injury to the lung would be expected to result age, 50.7 ± 3.5 days. (f) CF null mice transfected with in damage to this barrier and permit fluid to enter the pTRIAL10 on day 0 and day 10 and killed on day 12 (n alveolae. More serious injury can result in proteinous = 6); weight, 17.5 ± 1.4; age, 53.0 ± 2.6 days. exudate entry and changes in the lining cells such as swelling and proliferation of type 2 pneumocytes. In the Measurement of ion transporting properties of the bronchi, inhalation of irritants leads to increased mucus tracheal epithelium production and inflammatory changes which are then Gene transfer and CFTR expression were assessed ex vivo followed by conversion of the columnar epithelium to a by measuring short circuit current (SCC) in tracheas, voltsquamous epithelium. The absence of any of the above age clamped at zero potential, following the protocol of signs of damage argue in favour of no damage to the MacVinish et al. 13 lungs of the transfected mice. This evidence for the lack of toxicity of DC-Chol/DOPE is encouraging for its use Statistical analysis as a delivery vehicle in repeat dosing strategies.
To compare the SCC responses of wild-type, CF null and In summary, we show that a second delivery of pTRItransfected tissues a nonparametric Mann-Whitney U AL10CFTR2 complexed with DC-Chol/DOPE is as effectest with two tails was used, P Ͻ 0.05 being considered tive as the initial dose in restoring a functional cAMPsignificant. stimulated chloride channel to the tracheal epithelium and that no airway inflammation is associated with this Toxicity repeat dose. The plasmid used in this study is identical To assess potential toxicity, the lungs from treated and to that used in a recent phase I clinical trial in which six untreated animals were fixed in 10% buffered formolof the eight patients receiving the plasmid showed evisaline, processed and embedded in paraffin wax. Seven dence of functional change. 15 Based on the results of this micron sections were cut along the sagittal plane so that clinical trial, and the data obtained in these murine all lobes could be examined and stained with haematoxyexperiments, permission has been granted for a second lin and eosin. phase I clinical trial involving multiple dose delivery of pTRIAL10CFTR2 complexed with DC-Chol/DOPE to the nasal epithelium of CF patients.
